TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Incident Heart Failure (HF)
Endpoint domain: Mortality/survival
Primary endpoint: Ratio of CD4⁺ T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Probability of target attainment for bacterial eradication
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: General Symptomatic Index scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interpersonal sensitivity scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aggressive behaviour scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Paranoiac tendencies scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the whole-blood concentration-time curve of sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak concentration of sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Trough concentration of sirolimus
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of gastrointestinal decompression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Restitution of borborygmi
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Time of exhaustion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of thallium scintigraphy in depiction of lymphadenopathy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Conjunctival staining improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hyperemia improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vessel clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sore throat incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Dysphagia incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Mortality from coronary heart disease (CHD)
Endpoint domain: Mortality/survival
Primary endpoint: Mortality from acute myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Length of Stay (LoS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Intra-abdominal Abscess (IAA)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Adhesive Small Bowel Obstruction (ASBO)
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of surgical site infections (SSIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: NYHA status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival at least 1 year
Endpoint domain: Mortality/survival
Primary endpoint: Postprandial dominant power (DP) increment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percentage of normal 2-4 cpm slow waves
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: incidence of early posttympanostomy otorrhea
Endpoint domain: Adverse events/effects
Primary endpoint: Retention rate of FS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ilioinguinal nodal accumulation at 150 min
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gait ability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Therapeutic assistance required
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Therapist discomfort
Endpoint domain: Adverse events/effects
Primary endpoint: Mean number of passes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crossover to the other type of needle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: working memory impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: thought disorder
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: euphoria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: calendar of premenstrual experiences total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: behavioral factor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical factor score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: suppression of hunger
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: delay to the onset of eating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: missed appointments
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Progression to persistent allergic rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: excessive weight gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: peripheral oedema
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: P(a)O(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Skin barrier repair
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Skin redness (inflammation)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: low vision-related functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: sprint swim performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRPC prognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preterm Rupture of Membranes (PROM)
Endpoint domain: Adverse events/effects
Primary endpoint: Preterm Premature Rupture of Membranes (PPROM)
Endpoint domain: Adverse events/effects
Primary endpoint: Pediatric Risk of Mortality (PRISM) score
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of TP (transient paresthesia)
Endpoint domain: Adverse events/effects
Primary endpoint: cognitive task accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: gait symmetry adaptation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lifetime prostate cancer mortality reduction
Endpoint domain: Mortality/survival
Primary endpoint: quality of life for the post‐treatment period
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvements in caregivers' PBS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Reductions in children's problem behavior
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Achieving mean glucose concentration of 80 to 180 mg/dL at 72 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of hypoglycemia (glucose <65 mg/dL)
Endpoint domain: Adverse events/effects
Primary endpoint: serum BDNF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: spatial memory impairments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clinical recurrence rates
Endpoint domain: Mortality/survival
Primary endpoint: Cavg values for OA and TD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax values at steady state for OA and TD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of adverse events related to OA and TD
Endpoint domain: Adverse events/effects
Primary endpoint: days to relapse to heavy drinking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: global clinical outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: clinical cure rate at 14 days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete recovery time of motor nerve blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Regression time of sensory blockade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relative perceived effectiveness of PSAs
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: BISS scores before and after treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI-S-BP scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to remission
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: RSDI score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Asthma control score (ACQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: FEV(1) below 80% predicted
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Screening adherence
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Clinical attachment level (CAL) gains
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probing pocket depth (PPD) reductions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximal force increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum integrated EMG increase
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in CSA of the QF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bladder maximum volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Bladder residual urine volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: aerobic capacity (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size of the CS ostium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Albendazole sulfoxide plasma concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PZQ concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-efficacy for childbirth
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Perceived anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived pain
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum HER‐2 ECD levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to achieve goal feeding rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of placement attempts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aspiration events
Endpoint domain: Adverse events/effects
Primary endpoint: Histological negativity after IC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: palmar arch patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of RAO
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Rate of sex partners
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Rate of condomless sex acts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: postoperative mediastinal bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fibromyalgia Impact Questionnaire (FIQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum levels of TNFalpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Serum LPS level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Improved nitrogen balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Improved lymphocyte recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Clinical and radiographic success rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Achieved normoglycemia on therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Met hemoglobin A1C criteria for complete or partial diabetes remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ICU-free days to day 28
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality by day 90
Endpoint domain: Mortality/survival
Primary endpoint: Serum CDT concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vertebral fractures
Endpoint domain: Mortality/survival
Primary endpoint: non vertebral fractures
Endpoint domain: Mortality/survival
Primary endpoint: hip fractures
Endpoint domain: Mortality/survival
Primary endpoint: Improvement under homeopathic treatment compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean myopia progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Levels of ghrelin and NPY
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of leptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: anesthesia efficiency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: anesthetic time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of correct answers
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Latent period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Period from induction to vaginal delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Perceived Stress Score (PSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Purchasing of fruit and dark-green/yellow vegetables
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: plasma S-nitrosothiols concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: plasma endothelin-1 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary nitrate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in serum E-selectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: exercise-induced heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean fat score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: flow-mediated vasodilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Number of medial tibiofemoral BMLs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital Anxiety and Depression Scale‐Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital Anxiety and Depression Scale‐Depression
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Levels of IL6
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of IL8
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Levels of TNFalpha
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in vertigo/dysequilibrium
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in speech discrimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of leg wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: Vein harvest time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Families' knowledge of teens' preferences for EOL conversations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: discontinuation due to hepatotoxicity
Endpoint domain: Adverse events/effects
Primary endpoint: cost per fully treated patient
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Age at onset of psychosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: GFR estimate using U-Cl(crea-urea)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Reproducibility of GFR estimation methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Readiness for discharge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: time to confirmed progression in disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement between manual and automated systems for nutrient-related goals
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: operative bleeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: bladder irrigation time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Regulation of immune function (CD3+ and CD4+ levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Hemorrhagic transformation (HT)
Endpoint domain: Adverse events/effects
Primary endpoint: MDA-LDL concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: MDA-LDL/LDL-cholesterol ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Objective image quality evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: visceral pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Early diastolic velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Systolic peak velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Insomnia severity
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of life (Physical component)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Vesicoureteral reflux incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence rates of tobacco product use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ghrelin-stimulated GH secretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pancreatic polypeptide response to ghrelin infusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Skeletal muscle insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: number of new or newly enlarged hyperintense lesions on MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of disability progression confirmed at 12 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: normalised jerk in primary movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of jerk in primary movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of elevated intraocular pressure
Endpoint domain: Adverse events/effects
Primary endpoint: Rates of cataract
Endpoint domain: Adverse events/effects
Primary endpoint: Reductions in bone turnover
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: duration of artificial respiration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mean plasma zinc levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean ZPP/H and hematocrit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sellar area size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute gland area sensitivity for post treatment changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HpSA positivity at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: VLDL cholesterol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Heart failure prevalence in younger patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: sdLDL-C levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Lipid outcomes
Primary endpoint: Time to return to baseline mental status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery agitation
Endpoint domain: Adverse events/effects
Primary endpoint: RLSS in the infarct area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 180 day survival
Endpoint domain: Mortality/survival
Primary endpoint: Initiation of antidepressants
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention